Patent US2256388A successfully refreshed from Google Patents.
Patent US4886876A successfully refreshed from Google Patents.
US4886876A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Factor VIII coagulant polypeptides
Assignee: Scripps Research Institute
•
Filing: 1987-04-13
•
Granted: 1989-12-12
•
Expires: 2007-04-13
Abstract
Abstract Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.
Inventors
- 👤 Theodore S. Zimmerman
- 👤 Carol A. Fulcher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:50
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/36; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829
Claims Analysis
Total Claims: 57
Claim 1
Independent Claim
27 words
An active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR3##
Claim 2
Dependent Claim
27 words
An active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR3##
Claim 3
Dependent Claim
45 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of the active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR4## and the coagulant polypeptide recited in claim 1.
Claim 4
Dependent Claim
53 words
A biological preparation suitable for treatment of hemophilia-related clotting disorders which consist essentially of the active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR5## and the coagulant polypeptide of claim 1; and an inert carrier therefore.
Claim 5
Dependent Claim
17 words
A biological preparation as claimed in claim 3 which exhibits specific coagulant activity higher than 1800 units/mg.
Claim 6
Dependent Claim
33 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation consisting essentially of a biological preparation of claim 3.
Claim 7
Dependent Claim
15 words
The factor VIII:C coagulant polypeptide of claim 1, wherein the polypeptide is cleavable by thrombin.
Claim 8
Dependent Claim
18 words
The factor VIII:C coagulant polypeptide of claim 6, wherein the polypeptide is derived from a human plasma source.
Claim 9
Dependent Claim
29 words
A biological preparation suitable for treatment of hemophilia-related clotting disorders which consists essentially of the coagulant polypeptide recited in claims 1, 6, or 7 and an inert carrier therefor.
Claim 10
Dependent Claim
27 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation of claim 8.
Claim 11
Dependent Claim
44 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of the active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR6## and the coagulant polypeptide of claim 9.
Claim 12
Dependent Claim
53 words
A biological preparation suitable for treatment of hemophilia-related clotting disorders which consists essentially of the active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR7## and the coagulant polypeptide of claim 9 and an inert carrier therefore.
Claim 13
Dependent Claim
27 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation of claim 11.
Claim 14
Dependent Claim
8 words
An active coagulant polypeptide of the sequence: ##STR8##
Claim 15
Dependent Claim
8 words
An active coagulant polypeptide of the sequence: ##STR8##
Claim 16
Dependent Claim
23 words
An active coagulant polypeptide composition consisting essentially of an active coagulant polypeptide of the sequence: ##STR9## and the polypeptide recited in claim 13.
Claim 17
Dependent Claim
26 words
A factor VIII:C coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR10##
Claim 18
Dependent Claim
26 words
A factor VIII:C coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR10##
Claim 19
Dependent Claim
45 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of the active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR11## and the coagulant polypeptide recited in claim 15.
Claim 20
Dependent Claim
73 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of the active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR12## and an active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR13## and the coagulant polypeptide recited in claim 15.
Claim 21
Dependent Claim
53 words
A biological preparation suitable for treatment of hemophilia-related clotting disorders which consists essentially of the active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR14## and the coagulant polypeptide of claim 15; and an inert carrier therefor.
Claim 22
Dependent Claim
17 words
A biological preparation as claimed in claim 18 which exhibits specific coagulant activity higher than 1800 units/mg.
Claim 23
Dependent Claim
27 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation of claim 18.
Claim 24
Dependent Claim
81 words
A biological preparation suitable for treatment of hemophilia-related clotting disorders which consists essentially of the active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR15## and the active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR16## and the coagulant fragment of claim 15; and an inert carrier therefor.
Claim 25
Dependent Claim
17 words
A biological preparation as claimed in claim 21 which exhibits specific coagulant activity higher than 1800 units/mg.
Claim 26
Dependent Claim
27 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation of claim 21.
Claim 27
Dependent Claim
15 words
The factor VIII:C coagulant polypeptide of claim 15, wherein the polypeptide is cleavable by thrombin.
Claim 28
Dependent Claim
18 words
The factor VIII:C coagulant polypeptide of claim 24, wherein the polypeptide is derived from a human plasma source.
Claim 29
Dependent Claim
27 words
An active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR17##
Claim 30
Dependent Claim
27 words
An active factor VIII:C coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR17##
Claim 31
Dependent Claim
20 words
The factor VIII:C coagulant polypeptide of claim 26, wherein the polypeptide terminates at a thrombin cleavage site of factor VIII:C.
Claim 32
Dependent Claim
18 words
The factor VIII:C coagulant polypeptide of claim 27, wherein the polypeptide is derived from a human plasma source.
Claim 33
Dependent Claim
30 words
A biological preparation suitable for the treatment of hemophilia-related clotting disorders which consists essentially of the coagulant polypeptide recited in claims 1, 13 or 15 and an inert carrier therefor.
Claim 34
Dependent Claim
27 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation of claim 29.
Claim 35
Dependent Claim
80 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR18## said coagulant polypeptide terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR19## said coagulant polypeptide being cleavable by thrombin.
Claim 36
Dependent Claim
80 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR18## said coagulant polypeptide terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR19## said coagulant polypeptide being cleavable by thrombin.
Claim 37
Dependent Claim
98 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR20## said coagulant polypeptide being derived from a human plasma source and terminating at a thrombin cleavage site of factor VIII:C, and an active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR21## said coagulant polypeptide being derived from a human plasma source and being cleavable by thrombin.
Claim 38
Dependent Claim
98 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR20## said coagulant polypeptide being derived from a human plasma source and terminating at a thrombin cleavage site of factor VIII:C, and an active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR21## said coagulant polypeptide being derived from a human plasma source and being cleavable by thrombin.
Claim 39
Dependent Claim
29 words
A biological preparation suitable for the treatment of hemophilia-related clotting disorders which consists essentially of the coagulant polypeptides recited in claims 31 or 32 and an inert carrier therefor.
Claim 40
Dependent Claim
80 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR22## said coagulant polypeptide terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR23## said coagulant polypeptide being cleavable by thrombin.
Claim 41
Dependent Claim
80 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR22## said coagulant polypeptide terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR23## said coagulant polypeptide being cleavable by thrombin.
Claim 42
Dependent Claim
95 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR24## said coagulant polypeptide being derived from a human plasma source and terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR25## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin.
Claim 43
Dependent Claim
95 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR24## said coagulant polypeptide being derived from a human plasma source and terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR25## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin.
Claim 44
Dependent Claim
29 words
A biological preparation suitable for the treatment of hemophilia-related clotting disorders which consists essentially of the coagulant polypeptides recited in claim 34 or 35 and an inert carrier therefor.
Claim 45
Dependent Claim
113 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR26## said coagulant polypeptide terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR27## said coagulant polypeptide being cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR28## said coagulant polypeptide being cleavable by thrombin.
Claim 46
Dependent Claim
113 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR26## said coagulant polypeptide terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR27## said coagulant polypeptide being cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR28## said coagulant polypeptide being cleavable by thrombin.
Claim 47
Dependent Claim
138 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight in the range of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR29## said coagulant polypeptide being derived from a human plasma source and terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR30## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR31## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin.
Claim 48
Dependent Claim
138 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight in the range of about 92,000 and having the partial protein amino acid sequence at the N-terminus as follows: ##STR29## said coagulant polypeptide being derived from a human plasma source and terminating at a thrombin cleavage site of factor VIII:C, and an active coagulant polypeptide having a molecular weight in the range of about 79,000-80,000 and having a partial protein amino acid sequence as follows: ##STR30## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR31## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin.
Claim 49
Dependent Claim
29 words
A biological preparation suitable for the treatment of hemophilia-related clotting disorders which consists essentially of the coagulant polypeptides recited in claims 37 or 38 and an inert carrier therefor.
Claim 50
Dependent Claim
62 words
A biological preparation suitable for the treatment of hemophilia related clotting disorders which consists essentially of an active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR32## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin, and an inert carrier therefor.
Claim 51
Dependent Claim
62 words
A biological preparation suitable for the treatment of hemophilia related clotting disorders which consists essentially of an active factor VIII:C coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial protein amino acid sequence as follows: ##STR32## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin, and an inert carrier therefor.
Claim 52
Dependent Claim
27 words
The method of treating hemophilia-related clotting disorders, comprising administering to a host in need of such treatment an effective amount of a biological preparation of claim 40.
Claim 53
Dependent Claim
73 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight in the range of about 78,000-79,000 and having a partial amino acid sequence as follows: ##STR33## said coagulant polypeptide being cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial amino acid sequence as follows: ##STR34## said coagulant polypeptide being cleavable by thrombin.
Claim 54
Dependent Claim
73 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight in the range of about 78,000-79,000 and having a partial amino acid sequence as follows: ##STR33## said coagulant polypeptide being cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial amino acid sequence as follows: ##STR34## said coagulant polypeptide being cleavable by thrombin.
Claim 55
Dependent Claim
87 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight in the range of about 78,000-79,000 and having a partial amino acid sequence as follows: ##STR35## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial amino acid sequence as follows: ##STR36## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin.
Claim 56
Dependent Claim
87 words
An active factor VIII:C coagulant polypeptide composition consisting essentially of an active coagulant polypeptide having a molecular weight in the range of about 78,000-79,000 and having a partial amino acid sequence as follows: ##STR35## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin, and an active coagulant polypeptide having a molecular weight in the range of about 71,000-72,000 and having a partial amino acid sequence as follows: ##STR36## said coagulant polypeptide being derived from a human plasma source and cleavable by thrombin.
Claim 57
Dependent Claim
29 words
A biological preparation suitable for the treatment of hemophilia-related clotting disorders which consists essentially of the coagulant polypeptides recited in claims 42 or 43 and an inert carrier therefore.
References Cited (Backward Citations)
US4657894A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-12-11 | 1993-06-12 | 1993-12-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-12-11 | 1997-06-12 | 1997-12-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-12-11 | 2001-06-12 | 2001-12-12 | $7700.00 | Window Closed / Lapsed |